Logo image of ACAD

ACADIA PHARMACEUTICALS INC (ACAD) Stock Fundamental Analysis

NASDAQ:ACAD - Nasdaq - US0042251084 - Common Stock - Currency: USD

19.95  -0.34 (-1.68%)

After market: 19.95 0 (0%)

Fundamental Rating

6

ACAD gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. ACAD is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. ACAD has both an excellent growth and valuation score. This means it is growing and it is still cheap. This is a rare combination! This makes ACAD very considerable for value and growth investing!


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

ACAD had positive earnings in the past year.
In the past year ACAD had a positive cash flow from operations.
In the past 5 years ACAD always reported negative net income.
ACAD had negative operating cash flow in 4 of the past 5 years.
ACAD Yearly Net Income VS EBIT VS OCF VS FCFACAD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -100M -200M

1.2 Ratios

ACAD has a Return On Assets of 13.15%. This is amongst the best in the industry. ACAD outperforms 97.51% of its industry peers.
ACAD has a Return On Equity of 22.26%. This is amongst the best in the industry. ACAD outperforms 97.51% of its industry peers.
ACAD's Return On Invested Capital of 14.01% is amongst the best of the industry. ACAD outperforms 97.16% of its industry peers.
Industry RankSector Rank
ROA 13.15%
ROE 22.26%
ROIC 14.01%
ROA(3y)-22.97%
ROA(5y)-26.99%
ROE(3y)-33.06%
ROE(5y)-35.55%
ROIC(3y)N/A
ROIC(5y)N/A
ACAD Yearly ROA, ROE, ROICACAD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20 -40 -60 -80

1.3 Margins

ACAD's Profit Margin of 13.83% is amongst the best of the industry. ACAD outperforms 96.09% of its industry peers.
Looking at the Operating Margin, with a value of 12.08%, ACAD belongs to the top of the industry, outperforming 95.38% of the companies in the same industry.
The Gross Margin of ACAD (91.61%) is better than 93.78% of its industry peers.
In the last couple of years the Gross Margin of ACAD has remained more or less at the same level.
Industry RankSector Rank
OM 12.08%
PM (TTM) 13.83%
GM 91.61%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.38%
GM growth 5Y0.53%
ACAD Yearly Profit, Operating, Gross MarginsACAD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -50K -100K -150K

More info and screens

7

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), ACAD is creating some value.
The number of shares outstanding for ACAD has been increased compared to 1 year ago.
ACAD has more shares outstanding than it did 5 years ago.
There is no outstanding debt for ACAD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ACAD Yearly Shares OutstandingACAD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M
ACAD Yearly Total Debt VS Total AssetsACAD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

2.2 Solvency

An Altman-Z score of 3.58 indicates that ACAD is not in any danger for bankruptcy at the moment.
ACAD's Altman-Z score of 3.58 is fine compared to the rest of the industry. ACAD outperforms 76.55% of its industry peers.
ACAD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Altman-Z 3.58
ROIC/WACC1.48
WACC9.44%
ACAD Yearly LT Debt VS Equity VS FCFACAD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 200M -200M 400M 600M

2.3 Liquidity

ACAD has a Current Ratio of 2.29. This indicates that ACAD is financially healthy and has no problem in meeting its short term obligations.
ACAD has a Current ratio of 2.29. This is in the lower half of the industry: ACAD underperforms 73.71% of its industry peers.
A Quick Ratio of 2.11 indicates that ACAD has no problem at all paying its short term obligations.
The Quick ratio of ACAD (2.11) is worse than 74.07% of its industry peers.
Industry RankSector Rank
Current Ratio 2.29
Quick Ratio 2.11
ACAD Yearly Current Assets VS Current LiabilitesACAD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 200M 400M 600M

More info and screens

7

3. Growth

3.1 Past

ACAD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 184.78%, which is quite impressive.
ACAD shows a strong growth in Revenue. In the last year, the Revenue has grown by 47.05%.
Measured over the past years, ACAD shows a very strong growth in Revenue. The Revenue has been growing by 26.55% on average per year.
EPS 1Y (TTM)184.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%150%
Revenue 1Y (TTM)47.05%
Revenue growth 3Y18.03%
Revenue growth 5Y26.55%
Sales Q2Q%18.28%

3.2 Future

The Earnings Per Share is expected to grow by 53.74% on average over the next years. This is a very strong growth
Based on estimates for the next years, ACAD will show a quite strong growth in Revenue. The Revenue will grow by 14.36% on average per year.
EPS Next Y290.34%
EPS Next 2Y98.82%
EPS Next 3Y70.84%
EPS Next 5Y53.74%
Revenue Next Year35.55%
Revenue Next 2Y21%
Revenue Next 3Y17.43%
Revenue Next 5Y14.36%

3.3 Evolution

The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
ACAD Yearly Revenue VS EstimatesACAD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 500M 1B 1.5B
ACAD Yearly EPS VS EstimatesACAD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 2 -2 3

More info and screens

7

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 25.58, ACAD can be considered very expensive at the moment.
Compared to the rest of the industry, the Price/Earnings ratio of ACAD indicates a rather cheap valuation: ACAD is cheaper than 95.20% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of ACAD to the average of the S&P500 Index (29.63), we can say ACAD is valued inline with the index average.
Based on the Price/Forward Earnings ratio of 26.88, the valuation of ACAD can be described as expensive.
Compared to the rest of the industry, the Price/Forward Earnings ratio of ACAD indicates a rather cheap valuation: ACAD is cheaper than 93.07% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of ACAD to the average of the S&P500 Index (22.68), we can say ACAD is valued inline with the index average.
Industry RankSector Rank
PE 25.58
Fwd PE 26.88
ACAD Price Earnings VS Forward Price EarningsACAD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60 80

4.2 Price Multiples

95.74% of the companies in the same industry are more expensive than ACAD, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, ACAD is valued cheaper than 96.98% of the companies in the same industry.
Industry RankSector Rank
P/FCF 16.38
EV/EBITDA 19.28
ACAD Per share dataACAD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 1 2 3 4 5

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
ACAD has a very decent profitability rating, which may justify a higher PE ratio.
ACAD's earnings are expected to grow with 70.84% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.09
PEG (5Y)N/A
EPS Next 2Y98.82%
EPS Next 3Y70.84%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ACAD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ACADIA PHARMACEUTICALS INC

NASDAQ:ACAD (2/21/2025, 8:00:00 PM)

After market: 19.95 0 (0%)

19.95

-0.34 (-1.68%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06 2024-11-06/amc
Earnings (Next)03-03 2025-03-03/amc
Inst Owners99.56%
Inst Owner Change3.4%
Ins Owners0.27%
Ins Owner Change-2.57%
Market Cap3.32B
Analysts77.6
Price Target25.61 (28.37%)
Short Float %9.88%
Short Ratio5.99
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)25.9%
Min EPS beat(2)9.83%
Max EPS beat(2)41.97%
EPS beat(4)3
Avg EPS beat(4)37.91%
Min EPS beat(4)-9.66%
Max EPS beat(4)109.49%
EPS beat(8)5
Avg EPS beat(8)30.41%
EPS beat(12)8
Avg EPS beat(12)25.58%
EPS beat(16)12
Avg EPS beat(16)26.34%
Revenue beat(2)1
Avg Revenue beat(2)-0.34%
Min Revenue beat(2)-1.34%
Max Revenue beat(2)0.66%
Revenue beat(4)2
Avg Revenue beat(4)-0.64%
Min Revenue beat(4)-3.12%
Max Revenue beat(4)1.22%
Revenue beat(8)4
Avg Revenue beat(8)0.75%
Revenue beat(12)5
Avg Revenue beat(12)-1.07%
Revenue beat(16)6
Avg Revenue beat(16)-1.97%
PT rev (1m)0%
PT rev (3m)-0.68%
EPS NQ rev (1m)-12.45%
EPS NQ rev (3m)100.28%
EPS NY rev (1m)-0.88%
EPS NY rev (3m)24.83%
Revenue NQ rev (1m)-1.86%
Revenue NQ rev (3m)4.65%
Revenue NY rev (1m)0.08%
Revenue NY rev (3m)0.81%
Valuation
Industry RankSector Rank
PE 25.58
Fwd PE 26.88
P/S 3.57
P/FCF 16.38
P/OCF 16.37
P/B 5.75
P/tB 7.04
EV/EBITDA 19.28
EPS(TTM)0.78
EY3.91%
EPS(NY)0.74
Fwd EY3.72%
FCF(TTM)1.22
FCFY6.11%
OCF(TTM)1.22
OCFY6.11%
SpS5.58
BVpS3.47
TBVpS2.83
PEG (NY)0.09
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 13.15%
ROE 22.26%
ROCE 17.73%
ROIC 14.01%
ROICexc 131.18%
ROICexgc N/A
OM 12.08%
PM (TTM) 13.83%
GM 91.61%
FCFM 21.81%
ROA(3y)-22.97%
ROA(5y)-26.99%
ROE(3y)-33.06%
ROE(5y)-35.55%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.38%
GM growth 5Y0.53%
F-Score5
Asset Turnover0.95
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF 0
Debt/EBITDA 0
Cap/Depr 0.57%
Cap/Sales 0.01%
Interest Coverage 250
Cash Conversion 162.79%
Profit Quality 157.71%
Current Ratio 2.29
Quick Ratio 2.11
Altman-Z 3.58
F-Score5
WACC9.44%
ROIC/WACC1.48
Cap/Depr(3y)251.6%
Cap/Depr(5y)210.75%
Cap/Sales(3y)1.91%
Cap/Sales(5y)1.56%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)184.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%150%
EPS Next Y290.34%
EPS Next 2Y98.82%
EPS Next 3Y70.84%
EPS Next 5Y53.74%
Revenue 1Y (TTM)47.05%
Revenue growth 3Y18.03%
Revenue growth 5Y26.55%
Sales Q2Q%18.28%
Revenue Next Year35.55%
Revenue Next 2Y21%
Revenue Next 3Y17.43%
Revenue Next 5Y14.36%
EBIT growth 1Y172.64%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year293.93%
EBIT Next 3Y75.42%
EBIT Next 5Y71.62%
FCF growth 1Y278.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y278.93%
OCF growth 3YN/A
OCF growth 5YN/A